Comparative Pharmacology
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
DICUMAROL vs HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa). This prevents fibrin formation and clot propagation. It also inhibits factors IXa, XIa, and XIIa.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
Continuous IV infusion: Initial bolus of 5,000 units, then 1,000 units/hour (25,000 units/24h) adjusted based on aPTT. Typical infusion rate 10-20 units/kg/hour.
None Documented
None Documented
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
30–150 minutes (intravenous), dose-dependent; at therapeutic doses ~60 minutes; prolonged in hepatic disease.
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Renal: negligible; biliary/fecal: negligible; primarily cleared by hepatic depolymerization and reticuloendothelial system uptake.
Category C
Category A/B
Anticoagulant
Anticoagulant